
Pozdeutinurad Lowers Serum Urate in Gout Trial, With Puja Khanna, MD, MPH
REDUCE-2 investigator Puja Khanna on gaps in oral urate-lowering therapy and why a selective URAT1 inhibitor was tested.
The American College of Rheumatology (ACR) recommends a treat-to-target strategy with a serum urate goal of <6 mg/dL for patients receiving urate-lowering therapy.¹ Pozdeutinurad (AR882), an investigational once daily oral URAT1 inhibitor, is designed to increase renal uric acid excretion rather than reduce uric acid production, as the xanthine oxidase inhibitors allopurinol and febuxostat do.²
Late-breaking data from the phase 3 REDUCE-2 trial were presented at
REDUCE-2 met its primary endpoint, with 69.2% of patients receiving pozdeutinurad 75 mg and 56.6% receiving 50 mg achieving serum urate <6 mg/dL at month 6, compared with 8.1% receiving placebo (both P < .0001).² Sobi reported clinically meaningful serum urate reductions as early as month 1, sustained through month 12.² Treatment-emergent adverse events occurred in 60.7%, 61.7% and 60.9% of patients in the 75 mg, 50 mg and placebo groups, respectively.²
“Achieving and maintaining target serum urate levels is fundamental to effective gout management, yet many patients remain inadequately controlled with currently available oral therapies, which can lead to permanent joint and tissue damage,” Puja P. Khanna, MD, MPH, professor of medicine in the Division of Rheumatology at the University of Michigan and a REDUCE-2 investigator, said in a statement.²
Pozdeutinurad is under evaluation in a broader phase 3 program, including the companion REDUCE-1 trial, in patients with gout, including those with uncontrolled and tophaceous disease.² In a written interview with HCPLive, Khanna discusses where care falls short for patients with uncontrolled gout on oral therapy, the rationale for testing a selective URAT1 inhibitor and the REDUCE-2 finding she considers most clinically meaningful.
Q&A: Uncontrolled Gout Gaps and the REDUCE-2 URAT1 Inhibitor Trial
HCPLive: For patients whose gout remains uncontrolled on currently available oral urate-lowering therapies, where do you see the biggest gaps in care today?
Puja P. Khanna, MD, MPH: The biggest gap is achieving and maintaining uric acid at recommended target levels of less than 6 mg/dL. While the 3 FDA-approved urate-lowering therapies, such as allopurinol, febuxostat and probenecid, are effective for many patients, some remain inadequately controlled. One size does not fit all, and there are always patients who are either unable to tolerate these medications or have some contraindications. Combining the oral medications increases pill burden, and patients often have difficulty staying compliant with these treatments. That unfortunately leads to suboptimal treatment of gout, where the uric acid continues to deposit and ultimately results in permanent joint and tissue damage. Additionally, the IV choice available is complex and costly.
HCPLive: What was the rationale for evaluating a selective URAT1 inhibitor in this population, and how was REDUCE-2 designed to test it?
Puja P. Khanna, MD, MPH: Pozdeutinurad is an investigational, once-daily oral therapy designed to selectively inhibit URAT1, a transporter in the kidney that plays an important role in the reabsorption of uric acid back into the bloodstream. By blocking URAT1, pozdeutinurad is designed to increase renal uric acid excretion and lower serum urate. This represents a different mechanism from oral therapies such as allopurinol and febuxostat, which are xanthine oxidase inhibitors that reduce the production of uric acid.
REDUCE-2 was designed as a global, double-blind, randomized, placebo-controlled phase 3 study. A total of 811 adults with gout were randomized 2:2:1 to once-daily pozdeutinurad 75 mg, pozdeutinurad 50 mg or placebo for 12 months. The primary endpoint was the proportion of patients achieving serum urate below 6 mg/dL at month 6.
HCPLive: What do you consider the most clinically meaningful finding from REDUCE-2, and why?
Puja P. Khanna, MD, MPH: I think the most important finding is the magnitude of serum urate lowering and the ability to sustain that effect over time. REDUCE-2 met its primary endpoint: at month 6, 69.2% of patients receiving pozdeutinurad 75 mg and 56.6% receiving 50 mg achieved serum urate below 6 mg/dL, compared with 8.1% receiving placebo, with both comparisons statistically significant at P < .0001. Reductions occurred rapidly following treatment initiation and were sustained through month 12.
That is meaningful because achieving and maintaining serum urate below 6 mg/dL over time is fundamental to effective gout management, yet some patients remain inadequately controlled with currently available oral therapies. Even if the patient was deemed eligible for IV therapy at the start of urate-lowering therapy, we would still need to switch back to an oral medication on a long-term basis. And now patients will have the choice of an efficacious, safe, more directed treatment that needs to be taken only once daily. A major gap in gout is overcoming the challenge of medication adherence, and pozdeutinurad also offers a ray of hope in changing this landscape.
Editors’ Note: Khanna reports relevant disclosures with Amgen, Arthrosi, Crystalys Therapeutics and Sobi. This transcript has been edited for grammar and clarity using artificial intelligence tools.
References
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi:10.1002/acr.24180
Sobi. Late-breaking phase 3 REDUCE-2 data show clinically meaningful and durable serum urate lowering with pozdeutinurad. Published October 29, 2026. Accessed November 19, 2026.
https://www.prnewswire.co.uk/news-releases/late-breaking-phase-3-reduce-2-data-show-clinically-meaningful-and-durable-serum-urate-lowering-with-pozdeutinurad-302923286.html Khanna P, Mandell B, Keenan R, et al. Treatment with URAT1 inhibitor pozdeutinurad (AR882) in a phase 3, double-blind, randomized study lowers serum urate levels in participants with gout [abstract LB20]. Arthritis Rheumatol. 2026;78(suppl 9). Accessed November 19, 2026.
https://acrabstracts.org/abstract/treatment-with-urat1-inhibitor-pozdeutinurad-ar882-in-a-phase-3-double-blind-randomized-study-lowers-serum-urate-levels-in-participants-with-gout/
Related to this article







